The entity was first described as â€œT–cell–rich B–cell lymphomaâ€ in 1988 by. . series of T/HRBCL likely underestimate modern response rates and survival as they .
All 59 newly diagnosed TC/HRBCL patients were treated with CHOP or R-CHOP combination chemotherapy +/- radiation therapy. The overall response rate was 85% and nine patients progressed on therapy. Fourteen patients relapsed with a median time of relapse of 6 months (range, 2 – 28).
Although T–cell–rich B–cell lymphoma (TCRBCL) is a recently recog- nized form. The actuarial and disease-free survival rates of the group at 5 years were 72% .
Disease, T–cell/histiocyte-rich large B cell lymphoma (THRLBCL) is a distinct. rate was obtained by chemoimmunotherapy, with a 5-year overall survival of .
lymphoma W Survival W B cells. Abstract. survival of T–cell–rich B–cell lymphoma (TCRBCL) pa-. er percentage of patients with TCRBCL presented with.
T–cell/histiocyte rich large B–cell lymphoma (THRLBCL) is a rare variant of diffuse large B-cell lymphoma. prognosis for patients with THRLBCL compared to. DLBCL.5 This. . this high relapse rate is the high rate of patients with stage IV .